资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.

Breast Cancer Res.. 2015;

DattaJashodeep，BerkErik，XuShuwen，FitzpatrickElizabeth，RosemblitCinthia，LowenfeldLea，GoodmanNoah，LewisDavid A，ZhangPaul J，FisherCarla，RosesRobert E，DeMicheleAngela，CzernieckiBri

Products/Services Used	Details	Operation
Peptide Synthesis	After plates were blocked, cryopreserved PBMCs, isolated using density gradient centrifugation, were plated in triplicate (2 × 105 cells/well) and incubated at 37 °C for 24–36 h with either HER2 peptides (4 μg; Genscript, Piscataway, NJ, USA); media alone (unstimulated control); or positive control (antihuman CD3/CD28 antibodies (0.5 μg/mL; BD Pharmingen, San Jose, CA, USA)).	Get A Quote

摘要

A progressive loss of circulating anti-human epidermal growth factor receptor-2/neu (HER2) CD4(+) T-helper type 1 (Th1) immune responses is observed in HER2(pos)-invasive breast cancer (IBC) patients relative to healthy controls. Pathologic complete response (pCR) following neoadjuvant trastuzumab and chemotherapy (T + C) is associated with decreased recurrence and improved prognosis. We examined differences in anti-HER2 Th1 responses between pCR and non-pCR patients to identify modifiable immune correlates to pathologic response following neoadjuvant T + C.